 WARREN, N.J., July 19, 2021 GLOBE NEWSWIRE -- Aquestive Therapeutics, Inc. NASDAQ: AQST, a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration FDA has accepted for filing the resubmission of the New Drug Application NDA for LibervantTM diazepam Buccal Film for the management of seizure clusters. The FDA has assigned a Prescription Drug User Fee Act PDUFA target goal date of December 23, 2021. 